About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359·38 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Tracy Nguyen
CONTACT
877-232-7974 info@adarx.com

Lead

ADARx Pharmaceuticals, Inc.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Mean eGFR greater than or equal to 30 mL/min/1.73m2
Clinical evidence of active kidney disease
Treated with supportive care including an ACE inhibitor or ARB if applicable
Willing to receive required vaccinations
Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy

You may not be if

Hereditary or acquired complement deficiency
Kidney transplant or renal replacement therapy
History of solid organ transplant
Other kidney disease
History of recurrent invasive infections
Received complement inhibitor treatments
Active systemic viral, bacterial, or fungal infection
Abnormal liver function

The record

StatusRecruiting

PhasePhase 2

Taking part45

StartedAug 2025

UpdatedSep 3, 2026

Conditions

IgAN C3G Complement-mediated Kidney Disease IgA Nephropathy (IgAN)IC-MPGN

Where38

ADARx Clinical Site
Doral, Florida, United States
ADARx Clinical Site
Miami, Florida, United States
ADARx Clinical Site
Pembroke Pines, Florida, United States

Clareo Health | Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease